Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Agsv Adjuvant

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06232954Not ApplicableUnknown

Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda

NCT03055000Phase 1CompletedPrimary

Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine

Showing all 2 trials

Research Network

Common Treatments

  • Agsv Adjuvant1
  • Agsv1
  • Mossiego Containing Untreated Blank Disc1
  • Mossiego Containing Treated Transfluthrin Disc1

Active Sponsors

  • Africa Power Limited1
  • Malaria Consortium1
  • ARCTECH INNOVATION LIMITED1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

Related Conditions

  • Malaria1

Activity Timeline